391 related articles for article (PubMed ID: 12031849)
1. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
Laufs U; Gertz K; Dirnagl U; Böhm M; Nickenig G; Endres M
Brain Res; 2002 Jun; 942(1-2):23-30. PubMed ID: 12031849
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice.
Laufs U; Gertz K; Huang P; Nickenig G; Böhm M; Dirnagl U; Endres M
Stroke; 2000 Oct; 31(10):2442-9. PubMed ID: 11022078
[TBL] [Abstract][Full Text] [Related]
3. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice.
Amin-Hanjani S; Stagliano NE; Yamada M; Huang PL; Liao JK; Moskowitz MA
Stroke; 2001 Apr; 32(4):980-6. PubMed ID: 11283400
[TBL] [Abstract][Full Text] [Related]
4. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
Jones SP; Gibson MF; Rimmer DM; Gibson TM; Sharp BR; Lefer DJ
J Am Coll Cardiol; 2002 Sep; 40(6):1172-8. PubMed ID: 12354446
[TBL] [Abstract][Full Text] [Related]
5. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Kilic U; Bassetti CL; Kilic E; Xing H; Wang Z; Hermann DM
Neuroscience; 2005; 134(3):901-6. PubMed ID: 16009498
[TBL] [Abstract][Full Text] [Related]
6. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
7. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
Stalker TJ; Lefer AM; Scalia R
Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
[TBL] [Abstract][Full Text] [Related]
8. Intravenous rosuvastatin for acute stroke treatment: an animal study.
Prinz V; Laufs U; Gertz K; Kronenberg G; Balkaya M; Leithner C; Lindauer U; Endres M
Stroke; 2008 Feb; 39(2):433-8. PubMed ID: 18162625
[TBL] [Abstract][Full Text] [Related]
9. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
Asahi M; Huang Z; Thomas S; Yoshimura S; Sumii T; Mori T; Qiu J; Amin-Hanjani S; Huang PL; Liao JK; Lo EH; Moskowitz MA
J Cereb Blood Flow Metab; 2005 Jun; 25(6):722-9. PubMed ID: 15716855
[TBL] [Abstract][Full Text] [Related]
11. Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
Mayanagi K; Katakam PV; Gáspár T; Domoki F; Busija DW
J Cereb Blood Flow Metab; 2008 Dec; 28(12):1927-35. PubMed ID: 18665182
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion.
Weinberg EO; Scherrer-Crosbie M; Picard MH; Nasseri BA; MacGillivray C; Gannon J; Lian Q; Bloch KD; Lee RT
Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1802-9. PubMed ID: 15563531
[TBL] [Abstract][Full Text] [Related]
13. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
Kilic E; Kilic U; Matter CM; Lüscher TF; Bassetti CL; Hermann DM
Stroke; 2005 Feb; 36(2):332-6. PubMed ID: 15625301
[TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase.
Suh JW; Choi DJ; Chang HJ; Cho YS; Youn TJ; Chae IH; Kim KI; Kim CH; Kim HS; Oh BH; Park YB
J Korean Med Sci; 2010 Jan; 25(1):16-23. PubMed ID: 20052342
[TBL] [Abstract][Full Text] [Related]
15. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
Landsberger M; Jantzen F; Könemann S; Felix SB
Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin preconditioning provides neuroprotection against spinal cord ischemia in rats through modulating nitric oxide synthase expressions.
Die J; Wang K; Fan L; Jiang Y; Shi Z
Brain Res; 2010 Jul; 1346():251-61. PubMed ID: 20513366
[TBL] [Abstract][Full Text] [Related]
17. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
Matsuo S; Saiki Y; Adachi O; Kawamoto S; Fukushige S; Horii A; Saiki Y
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):902-9. PubMed ID: 25454916
[TBL] [Abstract][Full Text] [Related]
18. Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity.
Ludolph B; Bloch W; Kelm M; Schulz R; Kleinbongard P
Vasc Health Risk Manag; 2007; 3(6):1069-73. PubMed ID: 18200826
[TBL] [Abstract][Full Text] [Related]
19. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.
Di Napoli P; Taccardi AA; Grilli A; De Lutiis MA; Barsotti A; Felaco M; De Caterina R
Cardiovasc Res; 2005 Jun; 66(3):462-71. PubMed ID: 15914111
[TBL] [Abstract][Full Text] [Related]
20. Effects of rosuvastatin on ADMA, rhokinase, NADPH oxidase, caveolin-1, hsp 90 and NFkB levels in a rat model of myocardial ischaemia-reperfusion.
Burma O; Onat E; Uysal A; Ilhan N; Erol D; Ozcan M; Sahna E
Cardiovasc J Afr; 2014; 25(5):212-6. PubMed ID: 25629537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
